Baralgetas - instructions for use, reviews, analogs and forms of release (tablets 500 mg, injections in injections) drugs for the treatment of headache and toothache, neuralgia in adults, children and pregnancy. Composition of pain medication

In this article, you can read the instructions for using the drug Baralgetas. There are reviews of visitors to the site - consumers of this medication, as well as opinions of doctors specialists on the use of an anesthetic Baralgetas in their practice. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of Baralgetas with available structural analogues.Use for the treatment of headache and toothache, neuralgia in adults, children, as well as during pregnancy and lactation. Composition of the preparation.

Baralgetas - a combined analgesic and antispasmodic agent, a combination of the components of the drug leads to a mutual enhancement of their pharmacological action.

Metamizole sodium - a derivative of pyrazolone, has an analgesic and antipyretic effect.

Pitofenone hydrochloride has a direct myotropic effect on smooth muscles (papaverin-like action).

Fenpiverinia bromide has m-holinoblokiruyuschim action and has an additional myotropic effect on smooth muscle.

Composition

Metamizol sodium + Pitophenone hydrochloride + Fentpuverinium bromide + excipients.

Indications

Pain syndrome (mild or moderate) with spasms of smooth muscles of internal organs: renal colic, spasm of ureter and bladder; biliary colic, intestinal colic; dyskinesia biliary tract, postcholecystectomy syndrome, chronic colitis; algodismenorea, diseases of the pelvic organs.

For short-term treatment: arthralgia, myalgia, neuralgia, ischialgia.

As an auxiliary medicine: pain syndrome after surgical interventions and diagnostic procedures.

Forms of release

Tablets 500 mg.

Solution for intravenous and intramuscular injection (injections in ampoules for injection).

Instructions for use and dosing regimen

Pills

Inside: adults and adolescents over 15 years: 1-2 tablets 2-3 times a day, without chewing, squeezed a small amount of liquid.

Children 12-14 years: single dose - 1 tablet, maximum daily dose - 6 tablets (1.5 tablets 4 times a day), 8-11 years - 0.5 tablets, maximum daily dose - 4 tablets (1 tablet 4 times a day) , 5-7 years - 0.5 tablets, the maximum daily dose - 2 tablets (0.5 tablets 4 times a day).

Ampoules

Parenterally (intravenously, intramuscularly).

Adults and adolescents over 15 years of age with acute severe colic are injected iv slowly (1 ml for 1 minute) 2 ml each; if necessary, re-injected after 6-8 hours. In / m - 2-5 ml of solution 2-3 times a day. The daily dose should not exceed 10 ml. Duration of treatment - no more than 5 days.

Calculation of the dose for children with / in and / m introduction: 3-11 months (5-8 kg) - only in / m - 0.1-0.2 ml; 1-2 years (9-15 kg) - in / in - 0.1-0.2 ml, in / m - 0.2-0.3 ml; 3-4 years (16-23 kg) - in / in - 0.2-0.3,in / m - 0.3-0.4 ml; 5-7 years (24-30 kg) - in / in - 0.3-0.4 ml, in / m - 0.4-0.5 ml; 8-12 years (31-45 kg) - in / in - 0.5-0.6 ml, in / m - 0.6-0.7 ml; 12-15 years - in / in and / m - 0.8-1 ml.

Before the injection of the injection solution, it should be warmed in the hand.

Side effect

• urticaria (including conjunctiva and mucous membranes of the nasopharynx);
• angioedema;
• malignant exudative erythema (Stevens-Johnson syndrome);
• toxic epidermal necrolysis (Lyell's syndrome);
• bronchospastic syndrome;
• anaphylactic shock;
• impaired renal function;
• oliguria;
• anuria;
• proteinuria;
• interstitial nephritis;
• staining the urine in red;
• a decrease in blood pressure;
• thrombocytopenia, leukopenia, agranulocytosis (can be manifested by the following symptoms: unmotivated rise in temperature, chills, sore throat, difficulty swallowing, stomatitis, and the development of phenomena of vaginitis or proctitis);
• dry mouth;
• decreased sweating;
• paresis of accommodation;
• tachycardia;
• difficulty urinating;
• with the / m introduction, infiltrates are possible at the injection site.

Contraindications

• hypersensitivity (including the derivatives of pyrazolone);
• oppression of bone marrow hematopoiesis;
• marked hepatic and / or renal insufficiency;
• deficiency of glucose-6-phosphate dehydrogenase;
• tachyarrhythmias;
• severe angina;
• decompensated chronic heart failure;
• angle-closure glaucoma;
• hyperplasia of the prostate (with clinical manifestations);
• intestinal obstruction;
• megacolon;
• collapse;
• pregnancy (especially in the first trimester and in the last 6 weeks);
• lactation period.

For IV introduction - infant age (up to 3 months) or body weight less than 5 kg. For tablets - children's age (up to 5 years).

Application in pregnancy and lactation

Contraindicated in pregnancy (especially in the first trimester and in the last 6 weeks).

Use in nursing mothers requires the cessation of breastfeeding.

Use in children

Contraindications for intravenous administration - infant age (up to 3 months) or body weight less than 5 kg; for tablets - children's age (up to 5 years).

Treatment of children under 5 years should only be carried out under the supervision of a doctor.

special instructions

During the treatment with the drug is not recommended to take ethanol (alcohol).

With prolonged (more than a week) treatment, control of the peripheral blood picture and the functional state of the liver is necessary.

If suspected of agranulocytosis or in the presence of thrombocytopenia should stop taking the drug.

It is not allowed to use acute pains in the abdomen for relief (until the cause is clarified).

Intolerance is very rare, but the threat of anaphylactic shock after IV injection is relatively higher than after taking the drug inside. Patients with atopic bronchial asthma and pollinosis have an increased risk of developing allergic reactions.

Parenteral administration should be used only in cases where oral administration is not possible (or absorption from the digestive tract is impaired). Special care is required when introducing more than 2 ml of solution (the risk of a sharp decrease in blood pressure). In / in the injection should be done slowly, in the "lying" and under the control of blood pressure, heart rate and BH.

When treating children under 5 years and patients receiving cytotoxic drugs, metamizole sodium intake should be done only under medical supervision.

For the / m introduction, a long needle should be used.

It is possible to stain urine in red by the release of a metabolite (it has no clinical significance).

Impact on the ability to drive vehicles and manage mechanisms

During treatment, care should be taken for drivers of vehicles and persons,engaged in potentially hazardous activities requiring quick physical and mental reaction.

Drug Interactions

The solution for injection is pharmaceutically incompatible with other drugs.

When co-administered with histamine with H1-blockers, butyrophenones, phenothiazines, tricyclic antidepressants, amantadine and quinidine, m-cholinoblocking action may be enhanced.

Strengthens the effects of ethanol (alcohol); simultaneous use with chlorpromazine or other derivatives of phenothiazine may lead to the development of severe hyperthermia.

Tricyclic antidepressants, oral contraceptives and Allopurinol increase the toxicity of the drug.

Phenylbutazone, barbiturates and other inducers of hepatic enzymes with simultaneous administration decrease the effectiveness of metamizole sodium.

Sedative and anxiolytic drugs (tranquilizers) increase the analgesic effect of metamizole sodium.

Radiopaque drugs, colloidal blood substitutes and penicillin should not be used during treatment with drugs containing metamizole sodium.

With the simultaneous administration of cyclosporine, the concentration of the latter in the blood decreases.

Metamizole sodium, displacing from the bond with protein oral hypoglycemic drugs, indirect anticoagulants, GCS and indomethacin, may increase the severity of their action.

Thiamazole and cytostatics increase the risk of developing leukopenia.

The effect is enhanced by codeine, H2-histamine receptor blockers and Propranolol (slows the inactivation of metamizole sodium).

Analogues of the drug Baralgetas

Structural analogs for the active substance:

• I took it;
• Bralangin;
• Geomag;
• Maxigan;
• Plenalgin;
• Revalgine;
• Renalgan;
• Spasgan;
• Spazmalgon;
• Spazmaline;
• Spazmoblok;
• Trinalgin.

Analogues for the pharmacological group (pyrazolones in combinations):

• Analginum quinine;
• Andipal;
• Antigrippin ARVI;
• Benalgin;
• I took it;
• Bralangin;
• Geomag;
• Maxigan;
• Otypax;
• Otyrerelax;
• Pentafuphene;
• Pentalgin;
• Piralgin;
• Plenalgin;
• Revalgine;
• Renalgan;
• Santoperalgin;
• Santotitralgin;
• Sedal M;
• Sedalgin Neo;
• Sedalgin Plus;
• Spasgan;
• Spazmalgon;
• Spazmaline;
• Spazmil M;
• Spazmoblok;
• Tempalgin;
• Tempanginol;
• Tetralgin;
• Trinalgin;
• Folikap.

Similar medicines:

Other medicines: